David Drobne

Appearances

ADDITIONAL RISANKIZUMAB THERAPY IS EFFECTIVE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO DID NOT ACHIEVE CLINICAL RESPONSE TO INITIAL 12-WEEK INDUCTION THERAPY: AN ANALYSIS OF PHASE 3 INSPIRE AND COMMAND STUDIES
Date
May 20, 2024
BACKGROUND: Risankizumab (RZB), an anti-interleukin 23p19 monoclonal antibody, demonstrated efficacy for moderately to severely active ulcerative colitis (UC) in the 12-week phase 3 INSPIRE induction study (NCT03398148)…
Presenter
Remo Panaccione
Speakers
Gil Melmed
David Drobne
Manreet Kaur
Mayo Clinic
Silvio Danese
Tadakazu Hisamatsu
Phillip Levine
Ezequiel Neimark
Su Chen
Ling Cheng
W Rachel Duan
Ramona Vladea
Patrick Hecht
Edouard Louis